STICH-3.0 International Trial Consortium

Recruiting now · Not applicable

Conditions studied: Coronary Artery Disease, Heart Failure

In brief

The primary objective of the STICH 3.0 Study is to determine whether CABG is superior to PCI in terms of all-cause mortality at 5 years in patients with severe CAD and iLVSD. Individual patient data from similar national RCTs independently powered for different efficacy endpoints will be pooled, harmonized, and analyzed. The primary endpoint is all-cause mortality.

Key facts

Study ID

NCT05761067

Run by

Vastra Gotaland Region

People needed

2800

Starts

2022-09-14

Expected to finish

2029-09-14

Last updated by the study team

2024-09-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >18 years
• LVEF ≤40%
• Extensive coronary artery disease (typically defined as a British Cardiovascular Intervention Society jeopardy score of ≥6, on a scale from 0 to 12, with higher scores indicating greater extent of disease).

You may not qualify if…

• Decompensated heart failure requiring inotropic/adrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump/ ventricular assist device therapy less than 48 hours prior to randomization;
• Valvular heart disease or any other cardiac conditions (e.g. LV aneurysm) indicating the need for surgical repair/replacement;
• Prohibitive bleeding risk or clinical scenario mandating avoidance of long-term dual antiplatelet therapy;
• Pregnancy;
• Circumstances likely to lead to poor treatment adherence;
• STEMI within 72 hours;
• PCI within 3 months.

Where it is running

• Dep of Cardiology, Sahlgrenska University Hospital — Gothenburg, Sweden (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.